452 related articles for article (PubMed ID: 34590792)
21. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
22. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract][Full Text] [Related]
23. Bioinformatics analyses proposed xenotropic and polytropic retrovirus receptor 1 as a potential diagnostic and prognostic biomarker and immunotherapeutic target in head and neck squamous cell carcinoma.
Wang L
Auris Nasus Larynx; 2023 Feb; 50(1):134-150. PubMed ID: 35690506
[TBL] [Abstract][Full Text] [Related]
24. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
[TBL] [Abstract][Full Text] [Related]
25. CERCAM is a prognostic biomarker associated with immune infiltration of macrophage M2 polarization in head and neck squamous carcinoma.
Yang Y; Yan C; Chen XJ
BMC Oral Health; 2023 Oct; 23(1):724. PubMed ID: 37803318
[TBL] [Abstract][Full Text] [Related]
26. Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Shi Y; Huang J; Hu Y; Shen Y
BMC Bioinformatics; 2023 Jun; 24(1):269. PubMed ID: 37386359
[TBL] [Abstract][Full Text] [Related]
27. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
[TBL] [Abstract][Full Text] [Related]
28. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
29. DOCK8 Serves as a Prognostic Biomarker and Is Related to Immune Infiltration in Patients With HPV Positive Head and Neck Squamous Cell Carcinoma.
Zhang Z; Bao Y; Zhou L; Ye Y; Fu W; Sun C
Cancer Control; 2021; 28():10732748211011951. PubMed ID: 33910393
[TBL] [Abstract][Full Text] [Related]
30. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
31. Ferroptosis-associated DNA methylation signature predicts overall survival in patients with head and neck squamous cell carcinoma.
Xu Y; Hong M; Kong D; Deng J; Zhong Z; Liang J
BMC Genomics; 2022 Jan; 23(1):63. PubMed ID: 35042463
[TBL] [Abstract][Full Text] [Related]
32. Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma.
Zhang S; Yu S; Wang J; Cheng Z
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33687056
[TBL] [Abstract][Full Text] [Related]
33. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
[TBL] [Abstract][Full Text] [Related]
34. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
[TBL] [Abstract][Full Text] [Related]
35. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape.
Zhang XY; Shi JB; Jin SF; Wang RJ; Li MY; Zhang ZY; Yang X; Ma HL
Cancer Commun (Lond); 2024 Jun; 44(6):670-694. PubMed ID: 38734931
[TBL] [Abstract][Full Text] [Related]
36. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
37. SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma.
Yang ML; Zhang JH; Li S; Zhu R; Wang L
Pathol Oncol Res; 2021; 27():1609967. PubMed ID: 34840533
[TBL] [Abstract][Full Text] [Related]
38.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
39. Exploring the Role and Prognostic Value of TMEM208 in Head and Neck Squamous Cell Carcinoma.
Yang J; Song T
Asian Pac J Cancer Prev; 2024 Mar; 25(3):909-919. PubMed ID: 38546073
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
